Skip to main content
polymarket watch expires 2027-01-01

Marijuana rescheduled by December 31, 2026?

DEMO Your position: YES 150 contracts @ 32¢ avg · -$6 (-12%)

Probability over time

Carver Thesis Tracker

Bullish/bearish reads aggregated from Carver-annotated regulatory events

  1. A
    DEA lowers schedule for marijuana ↑ 0 ↓ 0 direct

    By Dec 31, 2026, 11:59 PM ET, a final DEA action reclassifies marijuana (the whole plant/substance, i.e., recreational marijuana) from Schedule I to II–V. Not satisfied by rescheduling only cannabinoids/derivatives.

  2. B
    DEA unschedules marijuana ↑ 0 ↓ 0 direct

    By Dec 31, 2026, 11:59 PM ET, a final DEA action removes marijuana entirely from the Controlled Substances Act schedules (unscheduled).

Carver Signal Narrative

Regulatory pressure centers on DEA’s rescheduling rulemaking, but 2025–26 developments—state AG crackdowns, a multistate letter on federal-state enforcement, and OFAC fentanyl sanctions—are peripheral and offer no clear signal. The key federal decision remains pending; a final DEA action is still needed before the Dec 31, 2026 deadline.

Settlement entities

Drug Enforcement Administration · regulator Department of Health and Human Services · regulator Department of Justice · regulator Food and Drug Administration · regulator White House Office of National Drug Control Policy · regulator

Regulatory timeline (5)

Directional assessments (↑↓) are AI-generated from Carver's regulatory corpus and reflect estimated regulatory impact on contract odds. Not investment advice.

Resolution criteria

This market will resolve to 'Yes' if marijuana is rescheduled down from Schedule I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to 'No'. The primary resolution source will be official information from the U.S. government, however a consensus of credible reporting will also be used. Note: In April 2026, FDA-approved marijuana products and state-licensed medical cannabis were moved to Schedule III under President Trump's executive order. This market specifically tracks whether recreational marijuana (currently Schedule I) is rescheduled. If the DEA reschedules only specific cannabinoids or derivatives without reclassifying marijuana as a whole, that does not qualify. A DEA administrative hearing on full rescheduling is scheduled to begin June 29, 2026.